Canada silent heart attack market is estimated to grow modestly at a CAGR of around 8.4% during the forecast period. Canada has a considerable market of silent heart attack treatment due to the huge investment of government in healthcare facilities and the adoption of innovative technologies in the healthcare domain. Cardiac procedures and other heart surgeries are comparatively economical in Canada compared to the US. The cost of CABG and other cardiology surgeries in Canada is around 40-50% lower than the US. Moreover, Canada has more favorable government policies and regulations as compared to the US which enable Canadian citizens to reduce the cost of surgeries and hospital stay in the country Every Canadian has a health card issued by Provincial Ministry of Health to avail the benefits of healthcare program. It is estimated that around 70% of Canadian healthcare cost is paid or reimbursed by the Canadian Government.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/canada-silent-heart-attack-market
Canada silent heart attack market is segmented into diagnosis, treatment, and end-user. Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest x-ray, computed tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics and ambulatory surgical centers (ASCs). Due to the severe pain associated with silent heart attack, medications are primarily required to relieve pain as well as to reduce blood clotting and relax heart muscle. The drugs enable to improve the heart functioning, widen, or dilate blood vessels, minimize pain, and protect against any life-threatening heart rhythms.
The companies which are contributing to the growth of the Canada silent heart attack market include Abbott Laboratories Inc., Johnson & Johnson Services Inc., Pfizer Inc., Bayer AG, and Novartis AG. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
A full report of Canada Silent heart attack Market available @ https://www.omrglobal.com/industry-reports/canada-silent-heart-attack-market
Canada Silent Heart Attack Market Segmentation
By Diagnosis
- Electrocardiography (ECG)
- Magnetic Resonance Imaging (MRI)
- Computed Tomography (CT Scan)
- Echocardiography
- Others (Blood Test)
By Treatment
- Medication
- Surgery
- Angioplasty
- Bypass Surgery
- Heart Transplant
By End-Users
- Hospital & Clinics
- Ambulatory Surgical Centers
Company Profiles
- Astellas Pharma Inc.
- AstraZeneca PLC
- Bayer AG
- Boehringer Ingelheim GmbH
- Boston Scientific Corp.
- Hoffmann-La Roche Ltd.
- GlaxoSmithKline Plc
- Medtronic PLC
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Siemens AG
- Takeda Pharmaceutical Co. Ltd.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
